Back to Authors

Wingerchuk, Dean M.

https://orcid.org/0000-0003-1608-8206

A5008002660 | I1330342723

Mayo Clinic

Citations 118

Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension (3998)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.3998

Fulminant Transverse Myelitis and Reversible Cerebral Vasculopathy in an Aquaporin-4-Antibody Positive Patient With Active Systemic Lupus Erythematosus (2622)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2622

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1788

Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (1780)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1780

Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (1765)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1765

Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1658

Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1494

Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1299

Quantitative Gait Analysis Techniques Detect Change Congruent with Patient Perceptions after Corticosteroid Treatment: A Pilot Study of Short-Term Change in Progressive MS (P04.105)

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p04.105

Incidence and Clinical Characteristics of Secondary Progressive Neuromyelitis Optica (P02.149)

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p02.149